image
Healthcare - Medical - Diagnostics & Research - NASDAQ - IE
$ 158.95
0.322 %
$ 12.4 B
Market Cap
16.37
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Aug, 11, 2025.

The intrinsic value of one ICLR stock under the worst case scenario is HIDDEN Compared to the current market price of 159 USD, ICON Public Limited Company is HIDDEN

This DCF valuation model was last updated on Aug, 11, 2025.

The intrinsic value of one ICLR stock under the base case scenario is HIDDEN Compared to the current market price of 159 USD, ICON Public Limited Company is HIDDEN

This DCF valuation model was last updated on Aug, 11, 2025.

The intrinsic value of one ICLR stock under the best case scenario is HIDDEN Compared to the current market price of 159 USD, ICON Public Limited Company is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ICLR

image
$210.0$210.0$200.0$200.0$190.0$190.0$180.0$180.0$170.0$170.0$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.015 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 JulAug '25Aug '25
FINANCIALS
8.28 B REVENUE
1.99%
1.1 B OPERATING INCOME
14.82%
791 M NET INCOME
29.26%
1.29 B OPERATING CASH FLOW
10.82%
-267 M INVESTING CASH FLOW
-17.71%
-837 M FINANCING CASH FLOW
0.81%
2.02 B REVENUE
0.80%
259 M OPERATING INCOME
17.91%
183 M NET INCOME
18.70%
162 M OPERATING CASH FLOW
-39.53%
-41.1 M INVESTING CASH FLOW
-10.30%
-275 M FINANCING CASH FLOW
-8.96%
Balance Sheet ICON Public Limited Company
image
Current Assets 3.53 B
Cash & Short-Term Investments 539 M
Receivables 2.69 B
Other Current Assets 303 M
Non-Current Assets 13.3 B
Long-Term Investments 57.9 M
PP&E 530 M
Other Non-Current Assets 12.8 B
3.19 %15.93 %3.14 %75.60 %Total Assets$16.9b
Current Liabilities 2.8 B
Accounts Payable 705 M
Short-Term Debt 66.5 M
Other Current Liabilities 2.03 B
Non-Current Liabilities 4.56 B
Long-Term Debt 3.54 B
Other Non-Current Liabilities 1.02 B
9.58 %27.54 %48.08 %13.89 %Total Liabilities$7.4b
EFFICIENCY
Earnings Waterfall ICON Public Limited Company
image
Revenue 8.28 B
Cost Of Revenue 5.85 B
Gross Profit 2.44 B
Operating Expenses 1.34 B
Operating Income 1.1 B
Other Expenses 306 M
Net Income 791 M
9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b008b(6b)2b(1b)1b(306m)791mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
29.42% GROSS MARGIN
29.42%
13.26% OPERATING MARGIN
13.26%
9.56% NET MARGIN
9.56%
8.31% ROE
8.31%
4.69% ROA
4.69%
7.08% ROIC
7.08%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ICON Public Limited Company
image
1b1b1b1b800m800m600m600m400m400m200m200m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 791 M
Depreciation & Amortization 528 M
Capital Expenditures -168 M
Stock-Based Compensation 45.9 M
Change in Working Capital -56.5 M
Others -88.4 M
Free Cash Flow 1.12 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ICON Public Limited Company
image
Wall Street analysts predict an average 1-year price target for ICLR of $351 , with forecasts ranging from a low of $295 to a high of $379 .
ICLR Lowest Price Target Wall Street Target
295 USD 85.59%
ICLR Average Price Target Wall Street Target
351 USD 120.57%
ICLR Highest Price Target Wall Street Target
379 USD 138.44%
Price
Max Price Target
Min Price Target
Average Price Target
400400350350300300250250200200150150100100Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26Aug '26Aug '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership ICON Public Limited Company
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK , July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited ("ICON") to expand it's Phase II Clinical Trial for cancer patients suffering from skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). Additional regulatory approval for the Phase II clinical trial is expected from potentially three EU countries in the upcoming months. prnewswire.com - 1 week ago
ICON Public Limited Company (ICLR) Q2 2025 Earnings Call Transcript ICON Public Limited Company (NASDAQ:ICLR ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Barry Balfe - Chief Operating Officer Kate Haven - Vice President of Investor Relations Nigel Clerkin - Chief Financial Officer Steven A. Cutler - CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division David Howard Windley - Jefferies LLC, Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division Eric White Coldwell - Robert W. seekingalpha.com - 2 weeks ago
ICON: Lower Guidance Downside And Expanded Repurchase Plan ICON may be relatively undervalued, trading at a ~10% discount to IQVIA and offering an attractive ~7% free cash flow yield that markets seem to be responding to now. The CRO sector faces near-term headwinds from a weak biotech funding environment related to high interest rates and associated increased clinical trial cancellations and delays. Q2 is indicating to markets that there will eventually be a return to growth after the CRO industry comes off the easy-money-fueled innovation environment. seekingalpha.com - 2 weeks ago
Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates Icon PLC (ICLR) came out with quarterly earnings of $3.26 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $3.75 per share a year ago. zacks.com - 2 weeks ago
ICON Announces Results of Annual General Meeting DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting. businesswire.com - 2 weeks ago
ICON Reports Second Quarter 2025 Results DUBLIN--(BUSINESS WIRE)--ICON Reports Second Quarter 2025 Results. businesswire.com - 2 weeks ago
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performance scores of other large CROs, solidifying its position as a premier partner for early phase clinical. businesswire.com - 3 weeks ago
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (ICLR 0.92%) by selling 16,096 shares. The transaction was valued at $2.58 million. fool.com - 1 month ago
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer of choice. Acknowledging ICON's leadership in the application of innovative AI technologies in the industry, the organisation. businesswire.com - 1 month ago
ICON: With A 57% Drop, Trump Legislation, And Debt Reduction, Is The Stock Undervalued? The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to repurchase $750 million of its outstanding common shares. seekingalpha.com - 1 month ago
ICON plc Schedules Second Quarter 2025 Earnings Conference Call DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Second Quarter 2025 Earnings Conference Call. businesswire.com - 1 month ago
8. Profile Summary

ICON Public Limited Company ICLR

image
COUNTRY IE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 12.4 B
Dividend Yield 0.00%
Description ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Contact South County Business Park, Dublin, 18 https://www.iconplc.com
IPO Date May 15, 1998
Employees 41250
Officers Mr. Diarmaid Cunningham Chief Administrative Officer, General Counsel & Company Secretary Mr. Simon Holmes President of Corporate Investments & Partnerships Mr. Joe Cronin Chief Human Resources Officer Mr. Barry Balfe Chief Operating Officer Mr. David Green Vice President of Marketing Ms. Niamh Murphy Director of Corporate Communications Mr. Nigel Clerkin A.C.A. Chief Financial Officer Mr. Thomas N. O'Leary Chief Information Officer Dr. Steven A. Cutler MBA, Ph.D. Chief Executive Officer & Director Dr. John Climax Ph.D. Founder & Independent Non-Executive Director